ALC-0315

Overview

ALC-0315 is an ionizable lipid used as a key formulation component in lipid nanoparticles, especially in mRNA-Lipid Nanoparticle delivery systems. In this role, it helps package and transport messenger RNA into cells, supporting intracellular delivery of nucleic acid therapeutics. Ionizable lipids such as ALC-0315 are designed to be relatively neutral at physiological pH but to acquire positive charge in acidic environments, which can promote RNA encapsulation during formulation and facilitate endosomal escape after cellular uptake.

Biomedically, ALC-0315 is significant because it is one of the clinically relevant lipid components used in approved RNA therapeutics and vaccines, and it continues to serve as a benchmark in studies aimed at improving lipid nanoparticles for messenger RNA and self-amplifying RNA delivery. Recent work has also extended its relevance beyond therapeutic delivery into analytical surveillance, where it is treated as a target analyte for detection in biological samples.

Focus of Latest Publications

Recent publications have focused on ALC-0315 primarily as an ionizable lipid component of lipid nanoparticles (LNPs) used for nucleic acid delivery, with studies examining how formulation design affects delivery efficiency, payload distribution, biodistribution, and downstream biological activity. In one mouse pharmacokinetic study of an mRNA-loaded LNP encoding a monoclonal antibody, ALC-0315 concentrations were quantified by LC-MS alongside mRNA by qPCR and expressed antibody by ELISA after intravenous dosing. The lipid showed highest exposure in liver and spleen, while mRNA and the expressed antibody displayed distinct tissue distributions, underscoring that the carrier, payload, and translated protein can follow different whole-body pharmacokinetic trajectories.

Several studies evaluated ALC-0315 in the context of LNP formulation optimization for messenger RNA and self-amplifying RNA delivery. A dual-ionizable-lipid LNP formulation combining ALC-0315 with SM-102 was reported to achieve high encapsulation efficiency, controlled particle size, and improved in vivo mRNA delivery and protein expression relative to a conventional comparator formulation. In a separate study of cholesterol analogs, β-sitosterol-containing ALC-0315-based mRNA-LNPs showed increased bioluminescence in target organs compared with cholesterol-based controls, and the same platform was used to deliver MERTK mRNA in a rat model of retinal degeneration, restoring visual function. These findings collectively highlight the sensitivity of ALC-0315-based systems to lipid composition and post-processing conditions such as lyophilization.

ALC-0315 was also used as a benchmark in comparative studies of alternative delivery systems and in analyses of LNP quality attributes. A high-throughput screen of imidazolium lipid nanoparticles found that many candidates outperformed the clinical ionizable benchmark ALC-0315 in multiple cell types, while a lead formulation achieved comparable intramuscular luciferase expression and antibody titers, with stronger ovalbumin-specific IFN-γ+ T-cell responses. In another study, single-particle cylindrical illumination confocal spectroscopy was applied to ALC-0315 and DLin-MC3-DMA LNPs carrying mRNA and guide RNA, revealing heterogeneous cargo distributions and showing that ALC-0315 LNPs with higher co-encapsulated RNA copy numbers produced greater in vivo gene-editing activity in mice.

Beyond delivery performance, ALC-0315 has also been studied as an analytical target. An LC-HRMS method was developed to detect ALC-0315, SM-102, and MC3 in equine plasma as surrogate markers for LNP-mediated gene-doping surveillance, with ALC-0315 detected at very low limits of detection. Together, these publications portray ALC-0315 as a clinically relevant ionizable lipid used in mRNA-LNP platforms, with recent work emphasizing formulation engineering, tissue-specific pharmacokinetics, cargo heterogeneity, therapeutic efficacy, and analytical detectability.

Key Publications

NEWJun Whole-Body Pharmacokinetics of Ionizable Lipid, mRNA, and the Expressed Antibody following Intravenous Administration of mRNA-Loaded Lipid Nanoparticles. (The AAPS journal, 2026, PMID 42373925): "Ionizable lipid (i.e., ALC-0315) concentrations were determined using LC-MS."
NEWJun Dual Ionizable Lipids (ALC0315 and SM102) in a Novel Lipid Nanoparticle Formulation Enhance In Vivo Delivery and Time-Dependent Expression of Messenger RNA and Self-Amplifying RNA. (ChemMedChem, 2026, PMID 42264921): "This study introduces a novel five-component LNP formulation incorporating ionizable lipid combination ALC-0315 and SM-102 with cholesterol, DSPC, and DMG-PEG-2000."
Jun Imidazolium Lipid-based Nanoparticles Enable Effective mRNA Delivery and Cellular Immune Response. (Materials today (Kidlington, England), 2026, PMID 42220328): "more than half of the library outperformed the clinical ionizable benchmark ALC-0315 in multiple representative mammalian cell types."
May LC-HRMS detection of three ionizable lipids in equine plasma: surrogate markers for long-term LNP-mediated gene-doping surveillance. (Analytical and bioanalytical chemistry, 2026, PMID 42135550): "the simultaneous detection of three clinically relevant ionizable lipids: ALC-0315, SM-102, and DLin-MC3-DMA (MC3), which are critical components of approved RNA therapeutics and vaccines."
Apr Messenger RNA and guide RNA distributions in lipid nanoparticles impact gene-editing efficiency in vivo. (Molecular therapy : the journal of the American Society of Gene Therapy, 2026, PMID 41981915): "In mice, ALC-0315 LNPs carrying higher cargo loads (9.8 vs. 8.0 mRNA copies and 25.4 vs. 20.3 gRNA copies per co-encapsulated particle) yielded 1.5-fold higher in vivo editing activity (55.4% vs. 36.3% insertions and deletions [indels]) despite nearly identical biophysical characteristics including LNP size and RNA encapsulation."
Jun Cholesterol analogs modulate lipid nanoparticle performance for mRNA delivery after lyophilization and enable ocular disease therapy. (Materials today. Bio, 2026, PMID 41953720): "β-sitosterol-formulated ALC-0315-based mRNA-LNPs and fucosterol-formulated MC3-based LNPs yielded increased bioluminescence in target organs."